Scholarlink

<p>Chronic myeloid leukemia (CML) is a&#xa0;myeloproliferative disease with a&#xa0;peak incidence in advanced adulthood. In childhood and adolescence, it is a&#xa0;rare form of leukemia compared to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The early manifestation is partly favored by the cooperation of constitutional germline variants with the oncogene <i>BCR::ABL1</i>. The clinical characteristics and treatment of pediatric CML in a&#xa0;growing organism are particular, requiring adaptation of the treatment strategies established for adults. Imatinib, dasatinib, nilotinib, and bosutinib are currently available as approved tyrosine kinase inhibitors (TKIs) for children and adolescents. Treatment with TKIs has also displaced allogeneic stem cell transplantation to subordinate lines of therapy in children. The side effect profile of TKIs in young patients varies to some extent from that in older patients. After maintaining a&#xa0;deep molecular response over several years, some patients can achieve treatment-free remission.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chronische myeloische Leukämie bei Kindern und Jugendlichen

  • 期刊论文

  • 发表日期：

    2025年7月25日

查看全文
  • Meinolf Suttorp,
  • Markus Metzler

摘要

Chronic myeloid leukemia (CML) is a myeloproliferative disease with a peak incidence in advanced adulthood. In childhood and adolescence, it is a rare form of leukemia compared to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The early manifestation is partly favored by the cooperation of constitutional germline variants with the oncogene BCR::ABL1. The clinical characteristics and treatment of pediatric CML in a growing organism are particular, requiring adaptation of the treatment strategies established for adults. Imatinib, dasatinib, nilotinib, and bosutinib are currently available as approved tyrosine kinase inhibitors (TKIs) for children and adolescents. Treatment with TKIs has also displaced allogeneic stem cell transplantation to subordinate lines of therapy in children. The side effect profile of TKIs in young patients varies to some extent from that in older patients. After maintaining a deep molecular response over several years, some patients can achieve treatment-free remission.